AbCellera launches $200M stock offering to fund lead cancer programme
What's the deal? AbCellera Biologics (Nasdaq: ABCL), a clinical-stage biotechnology company, has commenced an underwritten public offering of $200 million in common shares and pre-funded warrants. The Canada-based company will use the net proceeds to advance its internal pipeline, including its lead clinical programme, ABCL635, plus working capital and general corporate purposes.
Who's involved? JefferiesDealroom has a profile for this one. Try Dealroom →, J.P. MorganDealroom has a profile for this one. Try Dealroom →, CantorDealroom has a profile for this one. Try Dealroom →, UBS Investment BankDealroom has a profile for this one. Try Dealroom →, and BMO Capital MarketsDealroom has a profile for this one. Try Dealroom → are acting as joint book-running managers. The offering runs under a shelf registration statement filed with the US Securities and Exchange Commission in February 2025.
What's the endgame? AbCellera focuses on discovering and developing first-in-class antibody-based medicines across endocrinology, women's health, immunology, and oncology. The raise gives it capital to push ABCL635 and other candidates through clinical development.
Why it stands out? The $200 million offering ranks in the 97.7th percentile among all-time post-IPO equity rounds for health companies in Canada, based on a sample of 624 deals. That places it near the top of comparable raises in the sector.
What could go wrong? The offering is subject to market and other conditions, and AbCellera says there is no assurance as to whether or when it may close, or as to the final size or terms. No securities are being offered in Canada or to Canadian residents.
The signal: Clinical-stage biotechs continue to tap public markets for the sustained capital needed to fund long, costly drug development. For AbCellera, the raise signals a shift toward advancing its own pipeline rather than relying solely on partnership-driven discovery work.
Image credit: National Institutes of Health (NIH)
Read more: MarketScreener
